RHHVF : Summary for ROCHE HLDGS AG GENUSSCHEINE NPV - Yahoo Finance

U.S. Markets open in 2 hrs 1 mins

Roche Holding AG (RHHVF)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
236.280.00 (0.00%)
At close: 3:59PM EST
People also watch
NVSEFNSRGFRHHBFHBCYFAHBIF
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close236.28
Open0.00
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume3,830
Market Cap203.58B
BetaN/A
PE Ratio (TTM)22.80
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Roche Gets Priority Review for Immunotherapy Drug Tecentriq
    Zacks7 days ago

    Roche Gets Priority Review for Immunotherapy Drug Tecentriq

    Roche Holding AG's (RHHBY) Genentech announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for cancer immunotherapy, Tecentriq.

  • Roche's (RHHBY) Lucentis Gets FDA Nod for Fifth Indication
    Zacks11 days ago

    Roche's (RHHBY) Lucentis Gets FDA Nod for Fifth Indication

    Roche Holding AG (RHHBY) announced today that the FDA has approved a label expansion of ophthalmology drug Lucentis- fifth indication.

  • American City Business Journals11 days ago

    Cambridge's Foundation Medicine gets new CEO in leadership shuffle

    Foundation Medicine has appointed a top Genentech commercial executive as its new CEO, the Cambridge cancer diagnostic firm announced Friday. Troy Cox, who previously led Genentech’s oncology portfolio, will take over as CEO of Foundation (FMI) beginning Feb. 6. The company said that its current CEO, Michael Pellini, who has served in that role since 2011, would become chairman of its board of directors on that date.